HUTCHMED (NASDAQ:HCM) Rating Lowered to “Hold” at Wall Street Zen

HUTCHMED (NASDAQ:HCM) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Several other research firms have also issued reports on HCM. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Stock Performance

Shares of NASDAQ HCM opened at $13.85 on Friday. HUTCHMED has a 12-month low of $11.51 and a 12-month high of $19.50. The stock’s fifty day simple moving average is $14.71 and its two-hundred day simple moving average is $14.96. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The firm had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $290.50 million. Equities analysts expect that HUTCHMED will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the period. M&G PLC grew its holdings in shares of HUTCHMED by 0.4% during the second quarter. M&G PLC now owns 259,617 shares of the company’s stock valued at $3,894,000 after buying an additional 924 shares during the last quarter. Amundi increased its position in shares of HUTCHMED by 41.9% in the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after acquiring an additional 65,898 shares during the period. Jane Street Group LLC increased its position in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the period. Finally, UBS Group AG raised its stake in HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.